#VisualAbstract Amivantamab-lazertinib is Effective for Epidermal Growth Factor Receptor Mutated Non-Small Cell Lung Cancer

Click here to read this study in NEJM.

©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

RELATED REPORTS

Simvastatin (Zocor) in combination with paclitaxel (Taxol) may provide treatment benefit compared to paclitaxel alone for small cell lung cancer

Pfizer’s Talzenna combo significantly delays prostate cancer progression

2 Minute Medicine: Pharma Roundup – Pfizer’s Talzenna delays prostate cancer progression, apixaban lowers VTE bleeding risk, Lilly’s retatrutide hits Phase III metabolic targets, and FDA warns Novo Nordisk over safety reporting violations [March 2026]

#VisualAbstract Amivantamab-lazertinib is Effective for Epidermal Growth Factor Receptor Mutated Non-Small Cell Lung Cancer

Simvastatin (Zocor) in combination with paclitaxel (Taxol) may provide treatment benefit compared to paclitaxel alone for small cell lung cancer

Pfizer’s Talzenna combo significantly delays prostate cancer progression

2 Minute Medicine: Pharma Roundup – Pfizer’s Talzenna delays prostate cancer progression, apixaban lowers VTE bleeding risk, Lilly’s retatrutide hits Phase III metabolic targets, and FDA warns Novo Nordisk over safety reporting violations [March 2026]

Multi-Organ Immune-related Adverse Events from Immune Checkpoint Inhibitors

The Scan by 2 Minute Medicine®: Kate Middleton’s Hair: Chemo Mysteries, MRI Screening: Is It Useful?, Biden’s COVID Amid Variant Surge, Avoiding Microplastics

RelatedReports

Simvastatin (Zocor) in combination with paclitaxel (Taxol) may provide treatment benefit compared to paclitaxel alone for small cell lung cancer

Pfizer’s Talzenna combo significantly delays prostate cancer progression

2 Minute Medicine: Pharma Roundup – Pfizer’s Talzenna delays prostate cancer progression, apixaban lowers VTE bleeding risk, Lilly’s retatrutide hits Phase III metabolic targets, and FDA warns Novo Nordisk over safety reporting violations [March 2026]

Dipeptidyl peptidase-4 inhibitors may be associated with an increased incidence of malignancy

The Scan by 2 Minute Medicine®: Kate Middleton's Hair: Chemo Mysteries, MRI Screening: Is It Useful?, Biden's COVID Amid Variant Surge, Avoiding Microplastics

Association between Childhood Housing Insecurity and Adolescent Health Outcomes

A large language model demonstrates superior cost-effectiveness in screening heart failure candidates for clinical trials

Recent Reports